Thousands of people from the UK Health Agency added the Pfizer COVID-19 oral vaccine on Tuesday, April 12, to test the drug's effectiveness in people who receive numerous vaccinations.

Paxlovid, a combination of the new drug Pfizer and the old antibiotic ritonavir, was given to thousands of vaccinated people in the UK in February.

Paxlovid has now been added to the UK's National Panoramic Program, which provides immunizations to more patients while documenting how to get the most out of vaccines in adult vaccines. .

Paxlovid has been shown to reduce the relative risk of death or hospitalization by nearly 90% in clinical trials in a high-risk group given treatment for 5 days.

 Currently, it has been recommended to take it to the initial stage of COVID-19, but another trial was added last month with hospitalized patients. The UK has reported 170,000 deaths from COVID-19, and President Boris Johnson has said the vaccine could reduce the number of deaths among those who do not benefit from vaccines, called vaccines that are part of the plan to live with the virus. sickness. immunosuppressants.


Chief Health Officer Sajid Javid said in a statement: "As we learn to live with COVID-19, the UK continues to use the best treatments that have saved many lives. UK patients are most at risk."

The Panoramic Study is open to adults 50 or older, or people ages 18 to 49 who have a lower level of health that puts them at higher risk for heart disease.


Paxlovid, a second antibiotic supplement after molnupiravir, a tablet developed by Merck & Co and Ridgeback Biotherapeutics, has not performed well in clinical trials.

The Department of Health said 20,000 people took part in the Panoramic study to develop a profile of molnupiravir and an additional 17,500 people enrolled in Paxlovid.